Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and cemdisiran versus continued eculizumab or ravulizumab in paroxysmal nocturnal hemoglobinuria
2020-002761-33Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Pozelimab + cemdisiran switch arm with Continue anti-C5 standard-of-care arm (2 arms). Primary endpoint: Percent change in lactate dehydrogenase. Started Feb 2022; status: terminated.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-002761-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002761-33.